Walleye Capital LLC Has $6.41 Million Stake in RxSight, Inc. (NASDAQ:RXST)

Walleye Capital LLC grew its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 620.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 129,687 shares of the company's stock after acquiring an additional 111,681 shares during the period. Walleye Capital LLC owned 0.32% of RxSight worth $6,410,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in RXST. Amalgamated Bank lifted its stake in shares of RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company's stock valued at $71,000 after purchasing an additional 207 shares during the period. Principal Financial Group Inc. lifted its stake in RxSight by 0.7% in the third quarter. Principal Financial Group Inc. now owns 36,046 shares of the company's stock valued at $1,782,000 after buying an additional 240 shares during the period. Crossmark Global Holdings Inc. grew its position in shares of RxSight by 3.2% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company's stock worth $473,000 after buying an additional 242 shares during the period. RiverPark Advisors LLC increased its stake in shares of RxSight by 9.6% in the 2nd quarter. RiverPark Advisors LLC now owns 3,379 shares of the company's stock valued at $203,000 after acquiring an additional 297 shares during the last quarter. Finally, CWM LLC raised its position in shares of RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company's stock valued at $25,000 after acquiring an additional 371 shares during the period. 78.78% of the stock is owned by institutional investors and hedge funds.

RxSight Stock Performance

NASDAQ:RXST traded up $0.48 during mid-day trading on Friday, reaching $46.88. 254,146 shares of the company's stock were exchanged, compared to its average volume of 683,749. The firm has a market capitalization of $1.89 billion, a PE ratio of -56.48 and a beta of 1.19. RxSight, Inc. has a one year low of $28.88 and a one year high of $66.54. The business's fifty day simple moving average is $48.58 and its two-hundred day simple moving average is $52.26.

Insider Activity

In other news, Director Jesse Anderson Corley purchased 11,111 shares of the business's stock in a transaction dated Tuesday, November 12th. The stock was bought at an average price of $45.37 per share, with a total value of $504,106.07. Following the acquisition, the director now owns 468,571 shares in the company, valued at approximately $21,259,066.27. The trade was a 2.43 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Shweta Maniar sold 3,782 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total transaction of $173,518.16. Following the sale, the director now owns 10,902 shares in the company, valued at $500,183.76. This represents a 25.76 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,702 shares of company stock worth $3,059,197. Corporate insiders own 9.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of RxSight in a report on Tuesday, October 29th. They set a "buy" rating and a $72.00 price objective for the company. Wells Fargo & Company cut their price target on shares of RxSight from $68.00 to $54.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a "buy" rating and issued a $66.00 price target on shares of RxSight in a report on Friday, September 13th. Stifel Nicolaus dropped their price objective on shares of RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Finally, Oppenheimer cut their price objective on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 6th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.